PAUL LAURENCE E 4
4 · Valeant Pharmaceuticals International, Inc. · Filed May 14, 2012
Insider Transaction Report
Form 4
PAUL LAURENCE E
Director
Transactions
- Purchase
Common Stock, no par value
2012-05-14$51.03/sh+2,100$107,156→ 34,497 total - Purchase
Common Stock, no par value
2012-05-14$51.03/sh+2,900$147,987→ 37,397 total
Footnotes (1)
- [F1]This number represents common shares purchased by the officer, as well as other outstanding equity awards that were previously reported in Table 1.